Xenobiotica · 1988 · 31 citations · 9 references
PharmacyMedicinePharmacokineticsPharmacologyClinical PharmacologyDrug MetabolismRenal PharmacokineticsDrug DispositionDrug Half-lifeMetabolite IdentificationMetabolite KineticsCapillary Gas ChromatographyDiclofenac TherapyDrug Trough ConcentrationMetabolite PharmacokineticsRenal Elimination KineticsRenal Elimination PathwaysTerminal Half-life EstimationTrough Concentration Analysis
1. The kinetics of diclofenac (I) and five of its metabolites (II-VI) were investigated in three healthy volunteers and in six patients. Compounds I-VI were measured by capillary column gas chromatography in plasma and urine. 2. After a single 100 mg dose of diclofenac sodium to volunteers, the drug was absorbed rapidly and showed peak plasma levels of 10-12 nmol/g. The maximum concentrations of five metabolites were comparatively low (0.36-2.94 nmol/g). The mono- and dihydroxy metabolites (II-V) had apparent terminal half-lives similar to that of I (1-3 h), but the hydroxymethoxy metabolite (VI) had a half-life of about 80 h. Renal elimination of VI within 96 h was about 1% of dose and that of I-VI was 36% (free plus conjugated). 3. Following daily treatment with 2 x 75 mg of an experimental sustained release formulation to patients for 6-10 months, steady-state trough concentrations of I-V in plasma were low (average values: 0.23-0.57 nmol/g). The mean trough concentration of VI was comparatively higher at 3.69 +/- 0.91 nmol/g presumably reflecting its accumulation. Despite this it is unlikely to contribute to the drug's therapeutic activity, since it has been shown in laboratory tests to be devoid of anti-inflammatory activity.
9
Pharmacokinetics and Metabolism of the Anti-Inflammatory Agent Voltaren
H. Stierlin, P.H. Degen, J. W. Faigle et al. · Scandinavian Journal of Rheumatology · 1978 · 182 citations
Biotransformation of diclofenac sodium (Voltaren®) in animals and in man
H. Stierlin, J. W. Faigle, A. Sallmann et al. · Xenobiotica · 1979 · 178 citations